Batch release and batch disposition: the terms
Batch release is the formal decision that a batch of product meets all requirements and can be distributed or sold. Batch disposition is the broader term for any final decision on a batch: release, reject, or another documented outcome such as reprocessing. Every batch gets a disposition. Only some get released.
The decision belongs to the quality function, not to production or supply chain:
- US: 21 CFR 211.22(a) gives the quality control unit “the authority to approve or reject all components, drug product containers, closures, in-process materials” and drug products. Section 211.142(a) requires “quarantine of drug products before release by the quality control unit.”
- EU: Release is a two-step act. The manufacturer’s quality system releases the batch, and a Qualified Person (QP) certifies it. EU GMP Annex 16 defines certification as the QP’s recorded check that “represents the quality release of the batch before the batch is released for sale or distribution.”
- APIs: ICH Q7 section 2.22 lists “releasing or rejecting all APIs” among the quality unit duties that cannot be delegated.
For a checklist of the release documentation required in the US and EU, see Batch Release Checklist: Documentation Requirements in the US and EU.
The batch release process, step by step
Companies draw the process differently, but the evidence is the same. A typical sequence:
- Batch completed and quarantined. Finished product is held under quarantine status (physical or system-controlled) until disposition.
- Production review. Production checks that the batch record is complete and signs it. EU Chapter 4 section 4.20 requires approval by the person responsible for the processing operations.
- Laboratory testing complete. Section 211.165(a) requires “appropriate laboratory determination of satisfactory conformance to final specifications” before release, including identity and strength of each active ingredient.
- Batch record review by the quality unit. Section 211.192 requires the quality unit to review and approve all production and control records, including packaging and labeling, before release.
- Deviations, OOS results and investigations closed or assessed. ICH Q7 section 6.72 says “all deviation, investigation, and OOS reports should be reviewed as part of the batch record review.”
- Audit trail review of release-relevant data. FDA’s data integrity Q&A treats audit trails as part of the record the quality unit reviews. The EU’s 2025 draft Annex 11 goes further, saying reviews with direct impact on release “should be available to the QP at the time of batch release.”
- Change controls and regulatory status checked. The batch must be made under the registered process, at registered sites, with any changes approved where required.
- Disposition recorded. The quality unit (and, in the EU, the QP) records the decision and the system status changes from quarantine to released or rejected.
Steps 3 to 7 can run in parallel. Most release delays come from waiting on step 5: an open deviation that nobody has assessed for impact.
What a batch quality assessment covers
The phrase “batch quality assessment” is used for the evidence review that sits behind the release decision. It answers one question: is there anything about this batch, its materials, its process or its data that means it should not be released?
Annex 16 section 1.7 lists what a QP must be assured of before certifying. Several items apply to any release decision, wherever the site is:
| Area | What to confirm | Typical evidence |
|---|---|---|
| GMP compliance | All manufacturing and testing steps were done under GMP | Site audit status, batch record, training records |
| Supply chain | The supply chain, including starting material sites, is documented and qualified | Supplier qualification, audit reports |
| Registered details | Sites and process match the marketing authorization | Regulatory register, change control log |
| Records | ”All records are complete and endorsed by appropriate personnel” (Annex 16, 1.7.11) | Executed batch record, logbooks |
| Test results | Finished product QC data meet the specification | Certificate of analysis, LIMS results |
| Investigations | Investigations for the batch are completed to a sufficient level | Deviation, OOS and CAPA records |
| Data integrity | Changes to critical data are explained | Audit trail review report |
Annex 16 allows these checks to be delegated to trained staff or third parties, but the QP remains responsible. In practice, most QPs rely on a release checklist completed by QA reviewers, plus their own review of exceptions.
Disposition options
Not every batch is a simple pass or fail.
| Disposition | When it applies | Key control |
|---|---|---|
| Release | All requirements met | Recorded by the quality unit; QP certification in the EU |
| Reject | Fails specification or GMP requirements and cannot be recovered | Documented rejection; controlled destruction or return |
| Reprocess or rework | A defined procedure exists to bring the batch into specification | Section 211.115 requires written, approved reprocessing procedures and quality unit review |
| Hold | Open investigation or missing data | Batch stays in quarantine; status visible in the inventory system |
| Release with deviation | An unexpected deviation occurred but quality is not affected | EU Annex 16 section 3 sets strict conditions (below) |
Annex 16 section 3 lets a QP consider certifying a batch with an unexpected deviation only if registered specifications are still met and the deviation has been assessed through quality risk management. It must be “thoroughly investigated and the root cause corrected.” The QP may also need to add the batch to the stability program. This is not a shortcut: it requires the investigation to be finished before certification, not after.
There is no general “conditional release” in US drug GMP. Section 211.192 requires investigation of unexplained discrepancies “whether or not the batch has already been distributed,” which covers issues found after release, not decisions made before it.
Real-time release testing changes the evidence, not the decision
Under ICH Q8 and EMA’s guideline on real-time release testing (RTRT), some end-product tests can be replaced with process data such as in-line NIR measurements. EMA defines RTRT as “the ability to evaluate and ensure the quality of in-process and/or final product based on process data.” Parametric release for terminally sterilized products is “one form of RTRT.”
RTRT does not remove the release decision. The EMA guideline says approved RTRT “may form a basis” for release, but “more aspects need to be taken into account,” including GMP compliance and the marketing authorization. The batch record review becomes more important, because the process data now carries more of the quality evidence.
Where batch release goes wrong
- Release before review is finished. The most common pattern in FDA warning letters. One firm in ECA’s May 2026 summary released product whose batch records showed “no test results” for the active ingredient. Section 211.192 drew 164 FDA Form 483 observations in FY2025, per GMP Insiders.
- Open deviations with no impact assessment. The deviation is “under investigation” at release, with no documented reason why the batch is unaffected.
- Missing linked batches. Section 211.192 requires investigations to “extend to other batches” that may be affected. Release decisions on sister batches are made without checking.
- Quality unit procedures not followed. Section 211.22(d) was the most cited provision for drug manufacturers in FY2025, at 243 observations.
- Status not controlled in the system. Product is shipped from quarantine because the inventory system did not block it.
- Audit trails reviewed after release, or not at all.
Batch release checklist
- Batch is in quarantine status and blocked in the inventory system
- Batch record complete and signed by production
- All finished product tests complete and within specification
- Quality unit has reviewed all production, control, packaging and labeling records
- All deviations and OOS results for the batch are closed or have a documented impact assessment
- Related batches identified and assessed where an investigation applies
- Release-relevant audit trail entries reviewed
- Process, sites and materials match the registered details
- Disposition and the person deciding are recorded
- EU only: QP certification recorded in the register
Prepare release evidence with AskDona
Release takes days when evidence is spread across the batch record, LIMS, the deviation system and change control. AskDona reads those documents together and produces a release evidence summary: what is complete, what is missing, and which open items need a decision, each linked to its source page. Run a sample batch release assessment on a recent batch. AskDona shows the evidence; your quality unit or QP decides.
FAQ
What is batch release in pharma? The quality unit’s documented decision that a batch meets all specifications and GMP requirements and may be distributed.
What is batch disposition? The final documented decision on a batch: release, reject, reprocess or hold. Release is one possible disposition.
Who can release a batch? In the US, the quality control unit (211.22). In the EU, a Qualified Person certifies the batch under Annex 16. For APIs, the quality unit under ICH Q7.
Can a batch be released with an open deviation? In the EU, only under Annex 16 section 3 conditions, with the investigation done and the root cause corrected. In the US, the quality unit must review and resolve discrepancies under 211.192 before release.
How long does batch release take? It varies widely by product and system. Paper-based review commonly takes days to weeks; electronic records with review by exception can cut that sharply.
References
All pages opened and checked by October 14, 2026.
| Source | Type | Used for |
|---|---|---|
| 21 CFR Part 211 (eCFR) | US regulation | 211.22, 211.115, 211.142, 211.165, 211.192 |
| EU GMP Annex 16: Certification by a QP and Batch Release | EU GMP guideline (copy hosted by ECA) | QP certification, section 1.7, section 3 deviations |
| ICH Q7 (FDA) | ICH guideline | Sections 2.22, 6.70–6.72 |
| FDA, Data Integrity and Compliance With Drug CGMP: Q&A | FDA guidance | Audit trails as part of quality unit review |
| Draft revised Annex 11 (2025 consultation) | EU draft guideline | Audit trail review available to QP at release |
| EMA, Guideline on Real Time Release Testing | EMA guideline (copy hosted by TGA) | RTRT definition and release role |
| ECA, Five new Warning Letters – Four Batch Record Review Citations | Industry news | Warning letter example |
| GMP Insiders, FY2025 FDA inspection observations | Industry analysis of FDA data | Citation counts |